Hematology

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial

Retrieved on: 
星期一, 三月 11, 2024

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the U.S.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the U.S.
  • Phase 1a/1b study evaluating NX-2127 in adults with relapsed/refractory B-cell malignancies.
  • The partial clinical hold on the study was announced by Nurix on November 1, 2023, following the company’s communication to the FDA of its intention to transition to an improved manufacturing process.
  • “We are pleased with the timely resolution of the partial clinical hold, which allows us to reinitiate enrollment in the NX-2127 Phase 1 study utilizing drug product from our new manufacturing process,” said Paula G. O’Connor, M.D., executive vice president and head of clinical development at Nurix.

medac unveils new Global Corporate Brand

Retrieved on: 
星期一, 三月 11, 2024

After decades of impressive and successful growth, the company is now unveiling a new global brand to express the transformation as a global player and to extent global impact.

Key Points: 
  • After decades of impressive and successful growth, the company is now unveiling a new global brand to express the transformation as a global player and to extent global impact.
  • The newly established unified brand reflects medac’s commitment to excellence and its global reach, consolidating its position as a key player in the pharmaceutical industry.
  • With a new global brand positioning and design, the brand aims to pursue medac’s promises, such as customer proximity and high expertise.
  • The new brand identity is reflected in a new global corporate website, accessible at www.medac-group.com.

NMDP Awards 25th Annual ‘Amy Scholars’ Grant, Furthering Post-Transplant Research

Retrieved on: 
星期三, 三月 6, 2024

Cieri and Sacirbegovic in their research efforts to improve the lives of those battling blood cancers and blood disorders.

Key Points: 
  • Cieri and Sacirbegovic in their research efforts to improve the lives of those battling blood cancers and blood disorders.
  • We are especially grateful to the Moore family, who generously funded the Amy Scholars Research Program in 2024,” said Joy King, Chief Advancement Officer, NMDP, and Executive Director, NMDP.
  • Since 1998, NMDP has invested more than $12 million, funding 51 early-career investigators and helping them develop research portfolios and establish their laboratories.
  • “For years, we have supported groundbreaking research by collaborating with an extensive network of physicians and scientists in impacting outcomes.

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
星期五, 三月 1, 2024

CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2023 and provided a business update.

Key Points: 
  • “In 2024, we anticipate undergoing a significant transformation, maturing into a clinical-stage company and bringing the first-ever Prime Editing-based therapeutic candidate to patients.
  • This funding will allow Prime Medicine to progress two distinct strategies for applying Prime Editing to treat CF: hotspot editing and PASSIGE™ (Prime Assisted Site Specific Integrase Gene Editing).
  • Gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
  • In January 2024, Prime Medicine announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer.

MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

Retrieved on: 
星期二, 二月 27, 2024

CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).

Key Points: 
  • CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).
  • Dr. Vezan currently serves as Vice President, Global Clinical Development at BeiGene.
  • Vezan holds vast experience in guiding oncology assets through all stages of development, from research to clinical strategies and registration.
  • Dr. Remus Vezan commented, “It is my pleasure and privilege to join MAIA as scientific advisor and support the efforts of the MAIA team in advancing the clinical development of its first-in-class telomere targeting agent.

Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Retrieved on: 
星期五, 二月 23, 2024

BOSTON, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today presented data highlighting its expanded access program (EAP) for FDA-approved allogeneic stem cell therapy Omisirge® (omidubicel-onlv) and Phase 1 data for its allogeneic cryopreserved natural killer (NK) cell therapy candidate GDA-201 at the 2024 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). The hybrid meetings take place February 21-24 virtually and in person in San Antonio, Texas.

Key Points: 
  • The hybrid meetings take place February 21-24 virtually and in person in San Antonio, Texas.
  • “The data presented at Tandem provide further evidence of the potential of Gamida Cell’s nicotinamide (NAM) technology to develop potentially curative therapies by expanding and enhancing cells,” said Ronit Simantov, MD, Chief Medical and Scientific Officer of Gamida Cell.
  • It allowed for institutional variability in conditioning regimens and supportive care, more closely reflecting the real-world environment.
  • Patients were heavily pretreated with a median of six prior lines of therapy including CAR-T cell therapy and hematopoietic stem cell transplant.

InflaRx Appoints Jan Medina as Head of Investor Relations

Retrieved on: 
星期四, 二月 22, 2024

JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx.

Key Points: 
  • JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx.
  • Mr. Medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research.
  • Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “We are delighted to welcome Jan to our team.
  • Jan joins InflaRx from Olink Proteomics where he was Vice President, Investor Relations & Capital Markets.

Europe Medical Diagnostics Market Insights Report 2024-2028 with Competitive Analysis of Labcorp, Quest Diagnostics, Sonic Healthcare, Eurofins Scientific, Synlab and Medicover - ResearchAndMarkets.com

Retrieved on: 
星期五, 三月 8, 2024

The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
  • European medical diagnostics market is expected to reach US$109.91 billion in 2028, growing at a CAGR of 5.69%, for the time period of 2024-2028.
  • The report provides a comprehensive analysis of the European Medical Diagnostics Market.
  • The company profiles of leading players (Labcorp, Quest Diagnostics, Sonic Healthcare, Eurofins Scientific, Synlab and Medicover) are also presented in detail.

BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

Retrieved on: 
星期四, 三月 7, 2024

Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory MAHOGANY ( NCT05100862 ) trial, which is underway.

Key Points: 
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory MAHOGANY ( NCT05100862 ) trial, which is underway.
  • The application for R/R FL was also granted Fast Track Designation and Orphan Drug Designation by the FDA.
  • In a recent presentation, BRUKINSA showed sustained PFS benefit versus ibrutinib in a longer term follow up.
  • The global BRUKINSA development program includes more than 5,000 subjects enrolled to date in 29 countries and regions.

Children’s Hospital Los Angeles Study Finds Many Kids With Sickle Cell Anemia Lack Preventative Care

Retrieved on: 
星期三, 三月 6, 2024

Children with sickle cell anemia are vulnerable to serious infections and stroke, but many do not receive the preventative care that could help them stay healthier for longer, a Children’s Hospital Los Angeles study found.

Key Points: 
  • Children with sickle cell anemia are vulnerable to serious infections and stroke, but many do not receive the preventative care that could help them stay healthier for longer, a Children’s Hospital Los Angeles study found.
  • The researchers measured how many young children with sickle cell anemia received adequate preventative antibiotics to prevent infection and if children and adolescents with sickle cell anemia received annual brain ultrasounds to assess their stroke risk.
  • “What we found, unfortunately, was not what we’d hoped for,” says Ashaunta Anderson , MD, MPH, MSHS, Pediatrician at Children’s Hospital Los Angeles , who led the study.
  • Twice-daily doses of antibiotics, given consistently, can protect young children with sickle cell anemia from developing serious infections.